Amneal Pharmaceuticals (AMRX) Cash from Restructuring (2019 - 2020)
Amneal Pharmaceuticals (AMRX) recorded quarterly Cash from Restructuring of -$536000.0 in Q3 2020, down 105.05% quarter-over-quarter from $10.6 million in Q3 2019, and down 105.05% on a YoY basis from $10.6 million in Q4 2019.
Amneal Pharmaceuticals (AMRX) Cash from Restructuring (2019 - 2020) Analysis & Trends
Amneal Pharmaceuticals' Cash from Restructuring history runs 2 years deep, the most recent figure standing at -$536000.0 for Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Amneal Pharmaceuticals | 4.34 Bn | 4.33 Bn | 320.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -536,000.00 |
| Sep 30, 2019 | 10.61 Mn |